Cannabidiol (medication)
solution may be used as a medication as is sold under the brand name Epidiolex among others. It is taken by mouth. It was approved for medical use in the United States in June 2018 for treatment of two rare forms of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome. Cannabidiol is the first United States Food and Drug Administration -approved drug derived from the Cannabis plant. It is made by GW Pharmaceuticals. In September 2018, Epidiolex was placed by the United States Drug Enforcement Administration in Schedule V, the least restrictive schedule for controlled substances, notwithstanding Cannabis itself being in Schedule I of the Controlled Substances Act, for substances with "no currently accepted medical use".
In the European Union it is sold as Epidyolex.
The DEA's rescheduling any substance related to Cannabis was considered a "landmark" and "the first time in 46 years that has shifted its stance on a marijuana compound".
